GlassScriptPhysician profile
Rhonda Beth Infante
NPI 1760260392
$3,299.50
in general payments reported to CMS, 2019-2025
17 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $1,235 · 2024: $603 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.91 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $431.48 | 2025 | |
| Abiomed | $407.70 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $257.19 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $245.17 | 2023-2024 | Jynarque |
| Abbvie INC. | $242.65 | 2023 | |
| Axsome Therapeutics, INC. | $241.20 | 2025 | Auvelity |
| Gilead Sciences, INC. | $136.85 | 2025 | Yeztugo |
| Teva Pharmaceuticals USA, INC. | $130.00 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $126.89 | 2024 | |
| Neurelis, INC. | $125.00 | 2023 | Valtoco |
| Alnylam Pharmaceuticals INC. | $125.00 | 2024 | Onpattro |
| Ultragenyx Pharmaceutical INC. | $121.63 | 2025 | Dojolvi |
| Argenx US, INC. | $120.86 | 2023 | Vyvgart |
| Otsuka America Pharmaceutical, INC. | $120.39 | 2023 | Rexulti |
| Novo Nordisk INC | $120.39 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $112.62 | 2023 | |
| Neurocrine Biosciences, INC. | $109.89 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Infante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.